New brain injury drug on fast track status

The FDA recently awarded Pharmos’ traumatic brain injury drug a fast track status. The traumatic brain injury treatment is intended to treat secondary neuroprotective brain damage following the injury. Often times, there can be a secondary injury that occurs after the initial trauma has been suffered that can be extremely damaging.

According to Pharmos, the U.S. market of patients with traumatic brain injury is estimated to be more than $500 million, with international market potential in excess of $1 billion. Nearly 2 million American suffer a traumatic brain injury every year.

Leave a Reply